Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Nat Cancer. 2020 Jan 20;1(2):235–248. doi: 10.1038/s43018-019-0018-6

Fig 4. Predictive biomarker discovery using the PRISM Repurposing dataset.

Fig 4.

Prioritization of compounds based on strength of predictive models (Pearson score) and cell line selectivity (bimodality coefficient). Both known oncology (n = 997 compounds) and non-oncology (n = 3,443 compounds) sets contain compounds with high selectivity and predictability (strong model performance; upper right quadrant).